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 Abstract 
 
Understanding the molecular aggregation of therapeutic agents is particularly 
important when applying low doses of a drug to the surface of the skin. The aim of 
this study was to understand how the concentration of a drug influenced its molecular 
aggregation and its subsequent percutaneous penetration after topical application. A 
model drug tetracaine was shown to form a series of different aggregates across the 
µM (fluorescence spectroscopy) to mM (light scattering analysis) concentration range. 
The aggregate formation process was sensitive to the pH of the vehicle in which the 
drug was dissolved (pH 4, CMC – 11 µM; pH 8 CMC – 7 µM) and it appeared to 
have an impact upon the drug’s percutaneous penetration. At pH 4, increasing the 
concentration of the drug in the donor solution decreased the skin permeability 
coefficient (Kp) of tetracaine (13.7 ± 4.3 x 10
-3 cm/h - 0.06 ± 0.02 x 10-3 cm/h), whilst 
at pH 8, it increased the Kp (29.9 ± 9.9 x 10
-3 cm/h – 75.1 ± 41.7 x 10-3 cm/h). These 
data trends were reproduced in a silicone membrane and this supported the notion that 
the more polar aggregates formed at pH 4 acted to decrease the proportion of species 
available to pass through the skin, whilst the more hydrophobic aggregates formed in 
pH 8 increased the membrane diffusing species.  
 
 
  
Key words: Tetracaine; transport; aggregation; skin; penetration enhancer; pain; drug 
delivery
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Introduction 
 
Drug-vehicle interactions are known to have a significant influence on the ability of 
topically applied medicines to deliver actives into the skin [1, 2]. It has been previously 
shown that a certain degree of physical interaction between the active and the vehicle 
must occur to facilitate solubilisation of the drug, but if the physical interactions are too 
strong, then drug release from the product after application can be hindered [3].  
 
Drug-drug interactions are in equilibrium with drug-vehicle interactions in topical 
products and therefore, drug-drug interactions may also have the potential to modify the 
performance of a medicine applied topically to the skin. Several therapeutic agents that 
are formulated in skin products are known to exhibit strong drug-drug interactions, which 
can lead to aggregation in the solution state, but how this molecular aggregation 
influences the potential of a drug to penetrate into the skin has not previously received a 
lot of attention [4-6].  
 
Molecular aggregation is known to modify the physiochemical properties of a drug. For 
example, a drug’s lipophilicity, molecular size, degree of ionisation, hydrogen bonding 
can all change upon the formation of drug aggregates. These physiochemical property 
modifications brought about by concentration dependant molecular aggregation can 
influence drug permeation directly by modifying the drug-skin interactions [7-10]. 
However, the skin is a highly restrictive barrier. Therefore, if drugs generate aggregate 
clusters with a size of larger than 10 nm, they would be unlikely to pass directly into the 
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skin unless they could access the follicular transport route [11-15]. Thus, in order to 
understand the influence of drug aggregation on percutaneous penetration, attempts must 
be made to characterise the drug aggregates formed when applied to the surface of the 
skin. In addition, to elucidate how these drug aggregates influence percutaneous 
penetration, due consideration must be given as to how they affect the availability of the 
membrane diffusing molecules.  
 
Previous work has shown that when nano-sized drug aggregates are present in a solution 
added to the surface of the skin, they can slow down drug permeation [16]. This was 
assumed to be a consequence of the aggregation process reducing the quantity of free 
drug that was able to passively penetrate the membrane. In an ideal system, drug 
monomers would always be in equilibrium with the aggregated species and therefore, the 
interactions between the two systems may influence the quantity of molecules able to 
pass into the skin [17-19]. However, drug aggregation rarely follows the homogeneous 
process shown by simple surfactants due to the fact that their chemical structure is not 
designed specifically to confer amphiphilic properties like synthetic surfactant molecules. 
As a consequence, there is often not a single species of aggregate formed in solution. 
Rather, drugs can form different types of aggregates in a concentration dependant manner 
in a similar manner to polymers. This makes the interactions of these system hard to 
predict and it makes it feasible that the aggregation process could lead to either drug 
donor depletion during the transport of the drug [18, 20] or the availability of more 
molecules to take part in the transport process. [21, 22].  
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The aim of this project was to characterise the molecular aggregation of the model drug, 
tetracaine at low drug concentrations and to understand the influence of the molecular 
aggregation process on transmembrane transport. Tetracaine was selected as a model 
drug in this study because it is known to aggregate in aqueous solutions [4, 5]. In 
addition, it was selected as its clinical use is hindered by its high penetration lag time (30 
to 45 minutes). Reducing lag time could improve the drugs performance in patients as it 
is often used before venepuncture or venous cannulation [23]. The focus of the study was 
to understand the aggregation process at low drug concentrations as it was suspected that 
the aggregates formed would be very different to the high concentrations previously 
assessed [16]. As a consequence, at low drug concentrations, tetracaine aggregation was 
characterised by three techniques: photon correlation spectroscopy, to correlate with the 
previous work, fluorescence spectroscopy, to assess aggregation at low drug 
concentrations and Fourier transform infrared spectroscopy (FTIR), to understand the 
intermolecular interactions. It was hoped that these three techniques would allow the drug 
aggregation process to be understood at drug concentrations ranging from the µM to the 
mM concentration range. The study compared tetracaine aggregation and percutaneous 
penetration in an aqueous vehicle set at pH 4 and pH 8 in order to assess if the ionisation 
of the drug would influence the aggregation and thus the percutaneous penetration. These 
two pHs were selected because tetracaine is a weak base with pKa’s at the secondary and 
tertiary amine of 3.41 and 8.24 respectively at 32 °C. Using these pKa values at pH 4 it 
was predicted that 100 % of the tertiary amine would be ionised and 23 % of the 
secondary amine would be ionized, at pH 8 it was predicted that 72 % of the tertiary 
amine would be ionised and 28 % of tetracaine would be unionised. The drug transport 
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was studied using a porcine epidermis and a silicone membrane to understand the manner 
in which aggregation influences transport through barriers with and without the potential 
for follicular transport.  
 
Materials and Methods 
 
Materials 
 
Tetracaine free base (≥ 98%) and hydrochloric acid were purchased from Sigma Aldrich, 
UK. Ultrapure water (18.2 M) was used throughout this study. 
 
Test sample preparation 
 
Tetracaine solutions were prepared and adjusted to pH 4.0 or 8.0 using hydrochloric acid 
and equilibrated at 32 °C unless stated otherwise. Solutions were stirred for at least 24 h 
and the pH rechecked prior to analysis to ensure they were at equilibrium.  
 
Photon correlation spectroscopy 
 
The derived count rates were analysed by photon correlation spectroscopy (Malvern 
Nanoseries Zetasizer ZEN3600, Malvern Instruments Ltd, UK). Detection of the light 
scattering signal was achieved at a 173 ° backscattering angle with samples equilibrated 
at 32 °C using water as a dispersant (refractive index 1.33, viscosity 0.8872 cP). Each 
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measurement comprised of 10-14 runs. Triplicates of each sample were assessed.  
Fluorescence spectroscopy 
 
Fluorescence emission spectra were recorded using a fluorescence spectrometer fitted 
with a Xenon pulse lamp (Varian Cary Eclipse Fluorescence Spectrometer, Agilent 
Technologies, UK). Beer-Lambert’s law can only be applied over a limited range of 
optical densities and at a high sample optical density, attenuation due to absorption of the 
incident light or the emitted light can lead to a decrease in intensity and a possible change 
in spectral distribution [24, 25]. In light of the possibility of having a deviation in 
linearity due to the concentration of tetracaine and not the molecular aggregation, a 
Quartz fluorescence cells (Helima Fluorescence Cell, Helima UK Ltd., UK) with a 3 mm 
path length, with an off-centre illumination was used to record the measurements. 
Excitation and emission slits were fixed at 5 nm. In all measurements, the excitation 
wavelength was set at 310 nm. The samples were scanned from 320 to 450 nm at a 
wavelength scan rate of 120 nm/min with a PMT detector gain of 600 V. The data were 
smoothed with a Savitzky Golay function filter size 25 using the Cary Eclipse software. 
The experiments were performed at a temperature of 32 °C. The system was chemically 
stable over 6 days and the effect of ion pairing with the ions dissolved in the aqueous 
solution was not significant (Data not shown). 
 
Critical aggregation concentration (CAC) analysis 
 
Two methods were used to identify the CACs and their values were compared [26]. In 
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one of the methods, a second derivative function was applied to the data by using 
OriginPro (OriginPro version 8.6, Origin Lab Corporation, US). The data was fitted with 
a non-linear model before a Gaussian distribution function was applied to highlight the 
critical points, i.e. the regions where local minimum or maximum occurred. In the other 
method, the intersection of 2 linear models that were applied to the data was determined. 
The second of these two methods is traditionally used when determining the CMC of 
surfactants [27]. 
 
FTIR analysis 
 
Deuterated water (D2O, Sigma Aldrich, UK) was employed to analyse the tetracaine 
solutions as it dampened the solvent signal in the 1700 – 1300 cm-1 and 3000 – 2850 cm-1 
ranges. The samples were loaded into a demountable universal transmission cell system 
(Omni-Cell, Specac Ltd, UK) fitted with CaF2 windows and a 25 m Mylar spacer 
(Specac Ltd., UK). The pHs of the tetracaine solutions were maintained using DCl. All 
spectra were produced using 32 scans collected at a spectral resolution of 4 cm-1. The 
data was recorded using a Spectrum One spectrometer (Perkin-Elmer Ltd., UK) and 
analyzed with Spectrum software (version 10, Perkin-Elmer Ltd., UK). 
 
Tetracaine transport studies 
 
Two barriers were employed for the transport studies, silicone membrane (0.12 mm, 
GBUK Healthcare, UK, no pre-treatment required) and porcine epidermis. Fresh 
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untreated white adult porcine ears were obtained from a local abattoir (Evans and Sons, 
UK). Damaged ears were discarded. After cleaning under clear running deionized water 
and wiping the residue with clean wipes, visible hairs were trimmed carefully. The 
preparation of epidermal porcine skin was carried out by heat separation [28]. Porcine 
skin were immersed and gently stirred in deionised water at 60 C for 1 min. After 
removal from the deionized water, the skin was put on a corkboard with the dermal side 
down and the epidermis was carefully separated from the dermis with tweezers. The 
separated epidermis was washed with deionized water and floated on filter paper 
(Whatman no. 1, UK) to act as a support. The samples were wrapped in aluminium foil 
and stored at - 20 C for a maximum of up to 1 month [29]. The samples were thawed 
before use.  
 
The transport studies were carried out using upright individually calibrated Franz 
diffusion cells with an average surface area of 2.1 ± 0.1 cm2 and receptor compartment 
volume of 9.2 ± 0.5 mL. The barrier was cut, mounted and sealed with parafilm between 
two chambers of the glass diffusion cell with a 13 mm magnetic flea in the receiver 
chamber. The cells were inverted and filled with previously filtered and sonicated 
receiver fluid. A solution pH adjusted to pH 4.0 and 8.0, with HCl, was used as a receiver 
fluid for the silicone membrane transport studies to investigate the transport of tetracaine 
through a hydrophobic barrier. Phosphate buffered saline (pH 7.4) was employed as a 
receiver fluid for the porcine epidermis transport studies to mimic the skin environment. 
The transport studies were performed on a submergible magnetic stirrer plate in a pre-
heated water bath set at 37 °C to provide a membrane surface temperature of 32 °C. After 
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cell equilibration for 1 h, the cells were checked for leaks by inversion and visual 
inspection for back diffusion. Infinite doses (i.e. >  than the classical 2-5 mg / cm 2 used 
to mimic dosing in vivo) of tetracaine mixtures (1 mL) were applied uniformly to the 
surface of each membrane so that a good representation of flux could be gained without 
significant donor phase depletion. The donor compartment was covered with a parafilm 
to minimise donor phase evaporation. At predetermined time intervals, 1 mL aliquots 
were removed from the receiver phase and replaced with fresh receiver fluid to keep the 
liquid volume in the receiver compartment constant. The collected samples were analysed 
by HPLC.  A total of 5 replicates of each experiment were performed.  
 
Cumulative amounts of drug (ng) penetrating the unit surface of the membrane area (cm2) 
were corrected for sample removal and plotted against time (h). The steady-state flux (J) 
was calculated from the slope of the linear portion of the curve (R2 ≥ 0.98), using at least 
4 points with values above the assay limit of quantification (LOQ). The permeability 
coefficient of tetracaine was calculated using equation 1 [30]: 
 
   
  
  
                                               (Equation 1)               
 
where J represents the flux, Kp is the permeability coefficient of the permeant across the 
membrane and Cv is the concentration of the drug in the vehicle. The enhancement ratio 
(ER) due to the various additives were determined using the following equation:  
 
    
  
  
                                           (Equation 2) 
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where J1 and J2 are the steady-state transmembrane transport rate of tetracaine from the 
tetracaine and tetracaine-nanoparticle mixture respectively. Drug concentration and not 
drug thermodynamic activity was used throughout this study to set the drug levels in the 
experiments and discuss the data because it was not the intention of this study to directly 
compare the dug flux at pH 4 and pH 8, this has been published in previous work (16), 
rather the study sought to compare the trends within each different vehicle. The data 
display and interpretation reflected this important feature of the study design.  
 
Tetracaine quantification 
 
The quantification of tetracaine was performed using a reverse-phase HPLC system 
consisting of a pump with autosampler (Hewett-Packard series 1050, Agilent 
Technologies UK Ltd., UK) connected to a fluorescence detector (Shimadzu detector RF-
551, Shimadzu corp., Japan). The system was controlled via a computer with Chromeleon 
software (Dionex Corp., USA), which was also used to record and interpret the analytical 
data. The mobile phase comprised acetonitrile-methanol-acetate buffer (0.1 M) (25:25:50 
(v/v), pH 5.1) set at a flow rate of 1.0 mL.min-1. Tetracaine was separated using a Luna 3 
m C18(2) (150 X 4.6 mm) stationary phase (Phenomenex, UK) at room temperature 
with a 100 μL injection volume and the fluorescence detection at an excitation 
wavelength of 310 nm and an emission wavelength of 372 nm. The retention time for 
tetracaine was 4.2 min. The calibration curves were constructed on the basis of the peak 
area measurements using standard solutions of known tetracaine concentrations dissolved 
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in an identical fluid as the receiver phase for the transport studies, 10-4 HCl (pH 4 water). 
The assay was shown to be “fit for purpose” in terms of sensitivity (LOD – 4.08 ng/mL, 
LOQ – 74 ng/mL, n=25), precision (6 % CV), and linearity (R2 ≥ 0.99).  
 
Statistical Analysis 
 
All values were expressed as their mean ± standard deviation (SD). The statistical 
analysis of data was performed using the statistical package for social sciences, SPSS 
version 21, (IBM Corp., USA) with a significance level of 0.05. The normality (Sapiro-
Wilk) and homogeneity of variances (Levene’s test) of the data were assessed prior to 
statistical analysis. Transport data were analysed statistically using one-way analysis of 
variance (ANOVA) tests for normally distributed data and a non-parametric Kruskal-
Wallis tests for non-Gaussian distributed data. Post hoc comparisons of the means of 
individual groups were performed when appropriate using Dunnet’s test for normal 
distributed data and Games Howell test for non-Gaussian distributed data.  For all pair-
wise comparison of means, Student’s independent t-test or Mann-Whitney test was 
applied. Data were presented using OriginPro software (OriginPro version 8.6, OriginLab 
Corporation, US). 
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Results 
 
Tetracaine aggregation 
 
Tetracaine aggregation in the mM region was determined by photon correlation 
spectroscopy (Table 1). By applying a second derivative function to the plot of the 
tetracaine solution concentration vs the unattenuated light scattering signal (derived count 
rates), the first critical point (defined as the CAC in this methodology) significantly 
decreased (p<0.05) from 40 to 0.3 mM when the pH increased from 4 to 8. A similar 
trend of decreasing CAC as a function of increasing pH was observed when the 
intersection method was used to determine the CAC (Fig. 1), i.e., the CACs significantly 
decreased (p<0.05) from 95.10 mM in pH 4 to 2.91 mM in pH 8. As there was not a 
sharp increase in the derived count rate at the point of aggregate formation, the 
intersection method was thought to be less appropriate to determine the CAC compared 
to the second derivative method in the data sets gathered in this study. As shown in 
Figure 1, the intersection method failed to accurately pick out the point at which the light 
scattering of the solution first started to increase dramatically and therefore it was thought 
to be consistently overestimating the CAC concentration. 
 
The fluorescence spectroscopy measurements were able to detect aggregation in the M 
region (Table 1). When the second derivative method was applied, the CACs 
significantly decreased (p<0.05) from 16 to 10 M as pH increased from 4 to 8. When the 
CACs were calculated using the intersection method (Fig. 1), the CACs also significantly 
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decreased (p<0.05) from 11.06 M in pH 4 to 7.38 M in the pH 8 vehicle. Unlike the 
light scattering data, the fluorescence data analysis did not seem particularly sensitive to 
the method used to determine CAC and both were considered to be accurate methods to 
collect the data. The wavelength at which maximum fluorescence intensity occurred in 
the collected fluorescence spectra experienced a significant blue shift (p<0.05) from 373 
nm in pH 4 to 361 nm in pH 8 (Table 1, refer to supporting information for fluorescence 
spectrum).  
 
To probe the bonds formed between the aggregates in different tetracaine ionisation 
states, FTIR was employed. Based on the different CACs in different pH adjusted 
vehicles (Table 1), 100 mM of tetracaine was dispersed in pH 4 and 10 mM of tetracaine 
was dispersed in pH 8 to ensure that the FTIR measurements were analysing solutions 
with a high proportion of aggregates. The FTIR spectrum recorded for the tetracaine 
solutions showed significant visible shifts in the regions of interest (Fig. 2). The 
absorbance spectrum was normalised by the absorbance value at the CH3 region (2939 
cm-1) to correct for the possibility of different laser intensities when performing the 
measurements. As the pH increased from 4 to 8, a reduction in intensity of carbonyl 
group peaks (1690 and 1606 cm-1) and N-H bend (1526 cm-1) was observed. An increase 
in intensity at the region associated with carboxylate groups were formed (1469 cm-1) 
was also observed. 
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Tetracaine transport 
 
Since each CAC referred to a change in the solution state equilibrium, it was suggested 
that multiple critical points in the spectroscopy data that characterised the aggregates was 
a consequence of a different arrangement of the molecules in the solution. In accordance 
with this interpretation at a tetracaine concentration of 16 and 50 μM, at which two 
different forms of aggregates of tetracaine were thought to dominate in solution 
respectively at pH 4 (Table 1), were used as donor solutions for the transport studies to 
assess the effect of drug aggregation on membrane permeation.  
 
At a solution pH of 4, the permeability coefficient through the porcine epidermis 
significantly decreased (p<0.05) from 13.7 ± 4.3 to 0.06 ± 0.6 x 10-3 cm/h when the 
tetracaine concentration increased from 10 M to 1.05 M (drug saturation). When the 
same test solutions were applied to the silicone membrane, a significant decrease 
(p<0.05) from 0.7 ± 0.2 x 10-3 cm/h at 10 M to 0.034 ± 0.005 x 10-3 cm/h at saturated 
tetracaine concentration was observed. Across the 10 M to 1000 M concentration 
range, where aggregates were thought be present and change in properties (Table 1), the 
permeability coefficient through the silicone membrane remained unchanged (p>0.05) 
(Table 2, refer to supporting information for permeation profiles). The concentrations at 
which no change was observed in the silicone membrane were not tested in the porcine 
skin. 
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A different trend was observed in the permeation data when the pH was increased from 
pH 4 to pH 8 (Table 3, refer to supporting information for permeation profiles). The 
permeability coefficient through the porcine epidermis significantly increased (p<0.05) 
from 29.9 ± 9.9 to 75.1 ± 41.7 x 10-3 cm/h as the tetracaine concentration increased from 
10 M to 6.29 mM (saturated concentration) (Fig. 3). In the silicone membrane, the 
permeability coefficient also significantly increased (p<0.05) from 23.5 ± 6.2 to 201.5 ± 
38.2 x 10-3 cm/h. Unlike at pH 4, at pH 8 the increase in permeability coefficient seemed 
to occur gradually as the drug concentration was increased (i.e. at 40 M tetracaine donor 
solution the Kp was 48.1 ± 5.4 x 10
-3 cm/h). 
 
Discussion 
 
Tetracaine solution state interactions 
 
Tetracaine, also known as amethocaine, is an amphiphilic molecule which presents a 
positive charge at physiological pH. The drug’s chemical structure displays a hydrophilic 
region (amine portion) and a hydrophobic region (aromatic portion) and this predisposes 
the molecule to self-association in aqueous solution. At concentrations of more than 1 
mM, previous literature suggests tetracaine forms an aggregate [31-33], but there appears 
to be a difference of opinion in the literature as to whether tetracaine forms organised 
micelles [34-36] or random molecular aggregates [31, 37].  
 
There have been several studies that document tetracaine’s critical aggregation constant 
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(CAC). For example, Kitagawa et al. proposed tetracaine hydrochloride had a CAC of 38 
mM at 25 °C in an aqueous solution within the pH range of 4.5 to 5.7 [34] using an 
electrode method. A higher value of 128 mM was reported when surface tension, density 
and Kraft point measurements were used to determine the tetracaine CAC at pH 5.0 – 5.5 
[35, 38, 39]. The inconsistency of these previously reported tetracaine CAC values may 
be due to technical issues in performing the experiments, but it is more likely the variance 
is a consequence of the different analytical equipment used to determine the CACs. It is 
notable that both the analytical techniques reported in these previous studies have a 
relatively high limit of detection, i.e. in the mM range [31, 34, 36, 40, 41].  If the 
tetracaine aggregation process is not uniform, i.e. it does not form a set of homogeneous 
micelles, it is possible that aggregation could start at much lower concentrations and the 
techniques previously employed to characterise tetracaine aggregation in previous work 
may have been only captures aggregation events at higher concentration. The results 
gathered from photon correlation spectroscopy in the current study, which also has 
relatively high limit of detection for molecular aggregates, supports the theory that the 
previously reported values for CAC were probably aggregation changes rather than the 
initial aggregation event  because the CAC results at pH 4 (40 and 200 mM) were close to 
those reported previously in the literature [34, 35, 38, 39]. The CAC of tetracaine at pH 8 
does not appear to have been investigated before and therefore, no comparisons with the 
literature values could be made. The fluorescence spectroscopy used in the current study 
probes a lower range of concentrations compared to photon correlation spectroscopy and 
thus, it provides useful additional information that supplements the literature in this field. 
In this study it showed a change in tetracaine conformation in solution at 16 M in pH 4 
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and 10 M in pH 8. The lower values recorded in the fluorescence measurements for the 
CAC compared to the photon correlation spectroscopy experiments supported the notion 
that the latter was not actually recording the first aggregation event, i.e. the CAC but 
rather changes in the confirmation of aggregates that were already present in solution. 
The fluorescence method detects tetracaine aggregation as a consequence of the shielding 
of the electrons in the aromatic ring, which generates signal quenching, when tetracaine 
molecules come together. The deviation from linearity in the concentration titration 
experiments signified a quenching process and this was interpreted, at the low 
concentration used in this study, as aggregation. At higher drug concentrations, signal 
quenching can occur simply as a consequence of an increase in drug molecules in 
solution. However, as an off-centre cell and very low concentrations of tetracaine was 
used to avoid these effects. The ability of the fluorescence measurements to detect 
conformation changes, which lead to aggregation, was supported by the spectral shift in 
wavelength observed when the pH of the solution in which the drug was dissolved 
changed. 
 
Both photon correlation spectroscopy and fluorescence spectroscopy results showed that 
as the pH of the solution within which the tetracaine was dissolved increased, the critical 
points at which the aggregation events that the spectroscopy methods detected decreased. 
This phenomenon has been previously shown for other drug molecules. Attwood and 
Natarajan observed a higher critical micelle concentration at a low pH (0.5 – 5.5) in 5 
different piperazine drugs (trifluoperazine, opirpramol, thiopropazate, flupenthixol and 
clopenthixol) [42]. The structure of trifluoperazine is close to tetracaine. It has an 
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aromatic hydrocarbon and two nitrogen atoms which protonates at pKa 3.8 and 8.4. 
According to Attwood and Natarjan, the increase in CMC as pH decreases can be 
attributed to the increase in electrical charge of the molecule as the nitrogen atoms 
become protonated, which provides more pronounce amphiphilic properties and thus a 
greater propensity to form aggregates [42].  
 
Both the fluorescence and FTIR studies seemed to suggest that tetracaine ionization 
influenced the type of aggregates that were formed by the drug. In pH 8, the tetracaine 
aggregates included a significant proportion of unionized tetracaine molecules. These 
unionised molecules seemed to generate a more hydrophobic environment when they 
were encouraged to form aggregates according given the blue fluorescence wavelength 
shift in the fluorescence spectra at pH 8, but not at pH 4 (Table 1). A similar trend has 
previously been observed by Mertz et al. [43], who showed a fluorescence blue shift 
when tetracaine aggregates were subjected to molecules that were known to form 
hydrogen bonds. The infrared spectra analysis of the data collected in the current work 
suggested that the drug aggregates formed in the pH 8 vehicle were formed by the 
generation of stronger intramolecular bonding because the carbonyl bands of tetracaine in 
pH 8 decreased more in intensity as a consequence of aggregation compared to pH 4. An 
investigation by Guerin et al. observed a similar decrease in carbonyl band intensity, but 
they were also able to a decrease in the drug’s amine group peak intensity. The led to the 
hypothesis that tetracaine associated by stacking of the aromatic rings, involving mostly 
      tertiary association with some         ester and       
  bonds [44]. The amine bond could not be detected in the current study but it was 
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assumed that a similar interaction occurred between the tetracaine molecules in this work. 
 
Tetracaine is formulated at 0.15 M in commercially available topical products and hence, 
given the data reported in this study, it is likely that a significant proportion of the drug is 
presented to the human skin as aggregates when applied in the aqueous vehicles that are 
currently used to deliver this agent. It is therefore probable that the transport of a 
tetracaine product is significantly influenced by the aggregation state of the drug. 
Previous work has even suggested that drug aggregation may be the cause of the high lag 
time and low penetrating amount of tetracaine [16].  
 
Tetracaine transmembrane permeation 
 
The process of passive transmembrane penetration is commonly interpreted using Fick’s 
second law of diffusion which makes the assumption that the system is homogeneous, 
i.e., there are no ‘specific interactions’ between the components of the system (drug, 
vehicle and membrane) [45-47]. According to Fick’s second law of diffusion the 
permeability coefficient should be constant for a drug when changing the initial loading 
concentration of the permeating compound. Hence, any changes in permeability 
coefficient represent deviations from ideal scenario described by Fick’s law, which can 
be a consequence of drug-membrane, drug-vehicle or drug-drug interactions. 
 
The manner in which a molecule aggregates is a consequence of the free energy changes 
associated with the aggregated and non-aggregated forms of the drug. An equilibration 
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between non-aggregates and aggregates always exists in the solution state. Given its pKa, 
in aqueous solutions at pH 4, aggregates are most likely to be formed of charged 
tetracaine molecules. This has been substantiated by previous zeta potential 
measurements, which has demonstrated that the aggregates are positively charged in an 
aqueous solution [16]. There are two main hypotheses that can be generated to explain 
the decrease in the permeability coefficient of the drug when charged tetracaine 
aggregates were formed. One possible hypothesis is that tetracaine transport was driven 
by only non-aggregated molecules. As the concentration of tetracaine in the solution 
increased, more aggregation occurred and hence there was less availability of free 
molecules. Thus, the permeability of tetracaine decreased. Another possible hypothesis is 
that tetracaine transport was driven by both aggregates and non-aggregates. Charged 
molecules often permeate through the skin via the shunt route and it is possible that the 
charged tetracaine aggregates followed this pathway [48]. Hence, when aggregation 
occurred perhaps more of the tetracaine molecules followed the shunt pathway and, as 
this has a limited capacity for molecule transport unlike the passive transport through the 
cell barrier it slowed the overall permeation rate. Of these two hypotheses, the former is 
more likely owing to the similar trends obtained from silicone membrane and porcine 
skin, which suggested (as silicone does not have any pores) that the shunt route was not a 
major route of transport that was modified by molecular aggregation in this study. 
 
As there were a significant proportion of the tetracaine molecules that were uncharged 
when dissolved in an aqueous vehicle at pH 8, it was assumed that the aggregates formed 
at this pH were more hydrophobic than at pH 4. It may be possible that small uncharged 
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tetracaine aggregates could travel directly into the skin [49, 50]. The similar trend of 
increased permeation coefficient through the porcine membrane and silicone membrane 
suggests that aggregates do not travel through the shunt route and that a non-follicular 
route is favoured. There are two possible hypotheses to explain the increase in the 
permeability coefficient of tetracaine when aggregates were formed. The first hypothesis 
considers the monomers to be the only type of molecules which penetrates through the 
barrier. According to standard aggregation kinetics, to balance the dynamic equilibrium 
between the monomers and aggregates in the donor solution, when the monomers pass 
through the skin more aggregates dissociate into monomers to replenish the monomers 
that have entered the barrier. It may be the more hydrophobic aggregates have a greater 
propensity to supply the monomers quickly compared to the charged aggregates, which 
may have a low free energy in the polar solvent. While this hypothesis seems appealing, 
it fails on one critical aspect. The time to transport tetracaine across the stratum corneum 
is much slower than the time for aggregates to dissociate (around 10-4 to 10 s) [51]. As 
such, the rate-determining step of tetracaine diffusion through the skin should be 
controlled by the rate of tetracaine transport through the stratum corneum, not the rate of 
aggregate dissolution. The second hypothesis is that tetracaine transport is driven by both 
aggregates and non-aggregates [21]. An increase in tetracaine concentration provides a 
supply of both monomers and aggregates. If both of these molecules pass through the 
skin directly via a non-follicular route, it would result in an increase in permeability of 
tetracaine. Further work is needed to confirm this hypothesis, but in order to do this, a 
method to detect how very small aggregates interact with the skin is needed. 
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Conclusions 
 
Tetracaine appeared to form aggregates in aqueous solutions in the M range and this 
suggested that previous attempts to define the CAC in the mM concentration range may 
have been hindered by the limit of detection of the analytical equipment employed in the 
study.  At different ionisation states, the type of aggregates formed differed. In a pH 4 
vehicle, aggregates decreased tetracaine permeability coefficient but using pH 8, 
aggregates had the opposite effect. Thus, it seems plausible that the modification of drug 
aggregation could be an effective strategy to enhance tetracaine permeation through the 
skin. However, a detailed investigation of the effects of aggregation on drug transport at 
different concentrations should be performed. The importance of drug concentration was 
shown in this work through a comparison of the results obtained in the current study, at 
low tetracaine, concentrations, compared to those obtained at high tetracaine 
concentrations in previous studies [16]. It appeared that molecular aggregation had a 
more pronounced effect at lower concentrations and this should be considered when 
developing new topical formulations that employ molecules that have propensity to self-
associate. 
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Fig. 1. Graphs depicting critical aggregation constants (CACs) using photon correlation 
spectroscopy (left) and fluorescence spectroscopy (right) in pH 4, 6 and 8. 
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pH Critical aggregation constants 
(CACs) using photon 
correlation spectroscopy 
(mM) 
 Critical aggregation constants 
(CACs) using fluorescence 
spectroscopy (M) 
max (nm) 
Second 
derivative test 
Intersection 
of 2 linear 
slopes 
 Second 
derivative test 
Intersection 
of 2 linear 
slopes 
4 40, 200 95.10  16, 50, 600 11.06 373 
6 20, 100 53.25  16, 40 8.89 372 
8 0.3, 2 2.91  10, 32, 100, 200 7.38 361 
 
Table 1. Characteristics of tetracaine aggregation in different pHs using fluorescence 
spectroscopy and photon correlation spectroscopy, where max represents the wavelength 
at which maximum fluorescence intensity occurs. 
  
 30 
 
 
Fig. 2. FTIR data of tetracaine in pH 4 and 8.  
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Fig. 3. Permeation profile of various concentrations of tetracaine through porcine 
epidermis at pH 8. Each point represents mean ±standard deviation (n=5). 
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Concentration 
(M) 
Porcine epidermis  0.12 mm silicone membrane 
Flux (ng/cm2/h) 
Kp  
(10-3 cm/h) 
 Flux  
(ng/cm2/h) 
Kp  
(10-3 cm/h) 
10 36.2 ± 11.3 13.7 ± 4.3  2.0 ± 0.6 0.7 ± 0.2 
20 - -  3.4 ± 0.7 0.7 ± 0.1 
40 - -  9.4 ± 0.7 0.8 ± 0.1 
100 - -  13.6 ± 3.3 0.5 ± 0.1 
1000 - -   177.9 ± 44.6 0.7 ± 0.2 
1.05 X 106 (1.6 ± 0.6) x 10
4 0.06 ± 0.02  (9.4 ± 1.4) x 103 0.034 ± 0.005* 
 
Table 2. Steady state flux and permeability coefficients, Kp, of different concentrations of 
tetracaine in pH 4 across porcine epidermis and silicone membrane. Data represent mean 
± standard deviation of 3 independent tetracaine samples. * Significant differences were 
observed based on Games Howell test. 
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Concentration 
(M) 
Porcine epidermis  0.25 mm silicone membrane 
Flux (ng/cm2/h) 
Kp  
(10-3 cm/h) 
 Flux  
(ng/cm2/h) 
Kp  
(10-3 cm/h) 
10 79.1 ± 26.1 29.9 ± 9.9  62.2 ± 16.5 23.5 ± 6.2 
40 - -  508.5 ± 56.9 48.1 ± 5.4 
6.29 X 103 (1.2 ± 0.7) x 10
5 75.1 ± 41.7  (3.4 ± 0.6) x 105 201.5 ± 38.2 
 
Table 3. Steady state flux and permeability constants, Kp, of different concentrations of 
tetracaine in pH 8 across porcine epidermis and silicone membrane. Data represent mean 
± standard deviation of 3 independent tetracaine samples. * Significant differences were 
observed based on Games Howell test. 
 
 
